台灣臨床試驗主持人資料庫|TPIDB

2017-07-01 - 2020-08-22

Phase II

A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)

Condition/Disease

Recurrent or Progressive Glioblastoma following Initial Therapy
Test Drug

DSP-7888

Participate Sites
3Sites

Recruiting3Sites

魏國珍

Linkou Chang Gung Medical Foundation

Division of Orthopedics

2016-11-01 - 2019-07-31

Phase III

A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Condition/Disease

High Risk Locally Advanced Cervical Cancer
Test Drug

ADXS11-001

Participate Sites
6Sites

Terminated6Sites

張廷彰

Linkou Chang Gung Medical Foundation

Division of Obstetrics & Gynecology

2015-09-01 - 2021-02-19

Phase II

A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment.

Condition/Disease

moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma
Test Drug

PDR001

Participate Sites
4Sites

Not yet recruiting1Sites

Terminated3Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-01-15 - 2020-01-31

Others

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-06-01 - 2019-08-31

Phase II

An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE031C2201

Condition/Disease

Chronic Spontaneous Urticaria
Test Drug

QGE031

Participate Sites
3Sites

Terminated3Sites

鐘文宏

Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-09-01 - 2022-08-03

Phase III

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Condition/Disease

Chronic Spontaneous Urticaria (CSU)
Test Drug

QGE031/ligelizumab

Participate Sites
3Sites

Recruiting3Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Condition/Disease

Obesity
Test Drug

Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Condition/Disease

Hepatocellular Carcinoma (HCC)
Test Drug

ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Condition/Disease

Non-small cell lung cancer
Test Drug

HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華

Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-06-01 - 2018-12-31

Phase I

A prospective, open-label, dose escalation phase 1 first-in-human study to investigate the safety, and tolerability and to determine the maximum tolerated dose and recommended phase 2 dose of a recombinant anti-EGFR humanized monoclonal antibody, HLX07, in patients with advanced solid cancers

Condition/Disease

solid tumor
Test Drug

HLX07

Participate Sites
3Sites

Terminated3Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

Search Result

List